Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Nasdaq

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Feb 14, 2021 1:58pm

168 Views

Post# 32565093

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nasdaq

3burtc wrote: Dilution is a myth perpetrated by you and your aliases. NO fact in reality! Deal should be around the corner, connected to the Nuance deal, unless I'm wrong lol. Cheers everyone!

Dude - why do you constantly bring up aliases with me? Not sure what you think you've uncovered or how it advances your interests but this is why I put you on ignore the last time. Stop it with the childish advances and just offer your ideas. No one cares for the rest.

Love

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing